Kymera Therapeutics (KYMR) Capital Expenditures (QoQ) (2020 - 2026)
Kymera Therapeutics (KYMR) Capital Expenditures (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Kymera Therapeutics | 10.77 Bn | 10.11 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.54% |
| Dec 31, 2025 | 3,116.02% |
| Sep 30, 2025 | -73.96% |
| Jun 30, 2025 | 48.82% |
| Mar 31, 2025 | -50.11% |
| Dec 31, 2024 | 595.24% |
| Sep 30, 2024 | -104.03% |
| Jun 30, 2024 | -36.65% |
| Mar 31, 2024 | 914.30% |
| Dec 31, 2023 | 93.85% |
| Sep 30, 2023 | -237.23% |
| Jun 30, 2023 | 168.60% |
| Mar 31, 2023 | 373.65% |
| Dec 31, 2022 | -217.58% |
| Sep 30, 2022 | 69.52% |
| Jun 30, 2022 | 52.49% |
| Mar 31, 2022 | -46.21% |
| Dec 31, 2021 | 192.81% |
| Sep 30, 2021 | -51.12% |
| Jun 30, 2021 | 281.71% |